292 related articles for article (PubMed ID: 23459495)
1. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Bowker KE
Antimicrob Agents Chemother; 2013 Jun; 57(6):2451-6. PubMed ID: 23459495
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel A; Tomaselli S; Elliott H; Bowker K
Antimicrob Agents Chemother; 2011 Apr; 55(4):1436-42. PubMed ID: 21263054
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Werth BJ; Barber KE; Ireland CE; Rybak MJ
Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
[TBL] [Abstract][Full Text] [Related]
5. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect".
Werth BJ; Steed ME; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2013 Jun; 57(6):2664-8. PubMed ID: 23545533
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.
Keel RA; Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2011 Sep; 55(9):4028-32. PubMed ID: 21670184
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
Steed M; Vidaillac C; Rybak MJ
Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus.
MacVane SH; So W; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014 Dec; 58(12):7520-6. PubMed ID: 25288076
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ceftaroline fosamil in a staphylococcal murine pneumonia model.
Bhalodi AA; Crandon JL; Biek D; Nicolau DP
Antimicrob Agents Chemother; 2012 Dec; 56(12):6160-5. PubMed ID: 22985880
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic comparison of different antimicrobial regimens against Staphylococcus aureus bloodstream infections with elevated vancomycin minimum inhibitory concentration.
da Costa TM; Cuba GT; Morgado PGM; Nicolau DP; Nouér SA; Dos Santos KRN; Kiffer CRV
BMC Infect Dis; 2020 Jan; 20(1):74. PubMed ID: 31973753
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
MacGowan AP; Bowker KE; Noel AR
Antimicrob Agents Chemother; 2008 Apr; 52(4):1401-6. PubMed ID: 18227179
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the antibacterial activity of ceftaroline against clinical isolates of methicillin-susceptible and- resistant Staphylococcus aureus in Kuwait hospitals.
Alfouzan W; Boswihi SS; Dhar R; Udo E
J Infect Public Health; 2020 Oct; 13(10):1589-1591. PubMed ID: 32859552
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia.
García P; Moscoso M; Fernández MC; Fuentes-Valverde V; Pérez A; Bou G
Int J Antimicrob Agents; 2023 Jul; 62(1):106836. PubMed ID: 37150362
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.
Vidaillac C; Leonard SN; Rybak MJ
Antimicrob Agents Chemother; 2009 Nov; 53(11):4712-7. PubMed ID: 19738009
[TBL] [Abstract][Full Text] [Related]
17. Ceftaroline fosamil doses and breakpoints for Staphylococcus aureus in complicated skin and soft tissue infections.
Das S; Li J; Iaconis J; Zhou D; Stone GG; Yan JL; Melnick D
J Antimicrob Chemother; 2019 Feb; 74(2):425-431. PubMed ID: 30380060
[TBL] [Abstract][Full Text] [Related]
18. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
Sader HS; Flamm RK; Farrell DJ; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae.
Van Wart SA; Ambrose PG; Rubino CM; Khariton T; Riccobene TA; Friedland HD; Critchley IA; Bhavnani SM
Antimicrob Agents Chemother; 2014; 58(2):885-91. PubMed ID: 24277021
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
